PharmaCyte Biotech’s Novel Approach to Brain Cancer
May Be Company’s Silver Bullet
It is no surprise that PharmaCyte Biotech’s (OTCQB – PMCB - $0.1226 – Spec Buy) treatment for pancreatic cancer retains such a high profile in the oncology community. After all, the Company is about to embark on another mid-stage clinical trial to treat pancreatic cancer using its innovative flagship technology. What may surprise investors is that its clinical approach to treating brain cancer may end up as the Company’s secret weapon.
Ever since a 60 Minutes report on a novel, if not dangerous, approach to treating brain cancer was aired on CBS, the topic of brain cancer treatment has risen to the forefront of many operating in the oncology and scientific communities. On the surface, the approach appears to be pure madness, as patients in an early stage Duke University-led clinical trial that have been stricken with a deadly brain cancer, glioblastoma, are treated in a combination therapy with a re-engineered polio virus designed to kill cancer cells. Results have ranged from extraordinary to poor, but the concept of treating this deadly disease via out-of-the-box methods clearly has merit.
Enter PharmaCyte Biotech.
The Company’s Viridis Biotech subsidiary seeks to combine PharmaCyte Biotech’s Cell-in-a-Box® cellulose-based live cell encapsulation technology with constituents of Cannabis, known as cannabinoids, or cannabinoid-like compounds to develop unique treatments for difficult-to-treat and deadly forms of cancer, such as brain cancer. Some cannabinoids are prodrugs that must be converted into their cancer-killing form. These prodrugs will be used with the Cell-in-a-Box® technology in ways that optimize their anticancer properties while minimizing or even eliminating adverse side effects normally occurring with chemotherapy to treat cancers. This approach mirrors the Company’s approach to other cancers, such as pancreatic cancer whereby results have proven very effective, thus far.
The two most familiar cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD). While THC is associated with psychotropic effects, CBD is not. Therefore, CBD is preferred for medicinal purposes.
In the laboratory, cannabinoids have shown effectiveness against glioma (a type of brain cancer), and in mice, cannabinoids reduced tumor growth and spreading (metastasis) and were also shown to inhibit the growth of new blood vessels required for tumor growth. In 2006, in a small, early-phase clinical trial, THC was shown to be beneficial for patients in treating glioblastoma multiforme, a severe and deadly type of brain cancer, when safe (non-psychoactive) doses were used. Given the fact that the cannabinoids have proven, in early testing, to break through the blood brain barrier, the use of cannabinoids in combination with PharmaCyte Biotech’s Cell-in-a-Box® could emerge as the secret weapon to treat brain cancer.
To that end, In May 2014 PharmaCyte Biotech entered into a research agreement with the University of Northern Colorado (UNC) to perform initial research that will be necessary for the development of cannabinoid-based treatments for serious cancers. The UNC is working to identify a cell type that is capable of converting cannabinoid-like prodrugs into their cancer-killing forms. Once a satisfactory cell type is identified, the cells will be encapsulated using the Cell-in-a-Box® technology for use in combination with one or more cannabinoid prodrugs.
Progress on this front in 2015 is likely to serve as a major catalyst for a boost in the Company’s standing and market value as PharmaCyte Biotech emerges as a formidable player in the treatment of brain cancer, which is a market worth hundreds of millions of dollars annually.
For more information, refer to our previous sponsored PMCB Reports, Updates and Hot Topic Articles by visiting http://www.GoldmanResearch.com/
Senior Analyst: Robert Goldman
Rob Goldman founded Goldman Small Cap Research in 2009 and has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.
This Microcap Hot Topics Article was prepared for informational purposes only.
Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select format reflects the Firm’s internally generated stock ideas along with economic and stock market outlooks. Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored microcap research ideas that typically carry greater risks than those stocks covered in the Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research reports on profiled stocks in the Opportunity Research format typically have a higher risk profile, and may offer greater upside. In 2015, Goldman Small Cap Research has been compensated by a third party in the amount of $6500 for a research subscription service and a series of articles. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information published by the Company, or other firms. Goldman Small Cap Research relied solely upon information published by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.
A Goldman Small Cap Research report or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This publication does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com